<SEC-DOCUMENT>0001299933-11-001144.txt : 20110420
<SEC-HEADER>0001299933-11-001144.hdr.sgml : 20110420
<ACCEPTANCE-DATETIME>20110419173928
ACCESSION NUMBER:		0001299933-11-001144
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20110419
ITEM INFORMATION:		Submission of Matters to a Vote of Security Holders
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20110420
DATE AS OF CHANGE:		20110419

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CUMBERLAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001087294
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33637
		FILM NUMBER:		11768923

	BUSINESS ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE,
		STATE:			TN
		ZIP:			37203
		BUSINESS PHONE:		615-255-0068

	MAIL ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE
		STATE:			TN
		ZIP:			37203
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>htm_41389.htm
<DESCRIPTION>LIVE FILING
<TEXT>
<!-- CoverPageHeader start -->
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>
<HEAD>
<TITLE> Cumberland Pharmaceuticals Inc. (Form: 8-K) </TITLE>
</HEAD>
<BODY TEXT="#000000" BGCOLOR="#FFFFFF" ALINK="#0000FF" HLINK="#FF0000" VLINK="#800080">
<!-- Comment1 -->
<A NAME="DOCUMENT_TOP">&nbsp;</A>
<P>
<!-- CoverPageHeader end --><!-- CoverPageTitle START -->
<A NAME="DOCUMENT_TOP">&nbsp;</A>
<HR NOSHADE>
<P>
<P ALIGN="CENTER">
<FONT SIZE="4">
		UNITED STATES<BR>
	SECURITIES AND EXCHANGE COMMISSION
</FONT>
<BR>
<FONT SIZE="2">
	WASHINGTON, D.C. 20549
</FONT>
<P ALIGN="CENTER">
<FONT SIZE="5">
	FORM 8-K
</FONT>
<FONT SIZE="2">

</FONT>
</P>
<P ALIGN="CENTER">
<FONT SIZE="3">
	CURRENT REPORT
</FONT>
</P>
<P ALIGN="CENTER">
<FONT SIZE="2">
	Pursuant to Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934
</FONT>
</P>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM">
<TD WIDTH="51%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="44%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Date of Report (Date of Earliest Event Reported):
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	April 19, 2011
</FONT>
</TD>
</TR>
</TABLE>
<BR>
</CENTER>
<!-- CoverPageTitle END --><!-- CoverPageRegistrant START -->
<P ALIGN="CENTER"><!-- -->
<FONT SIZE="6">
	Cumberland Pharmaceuticals Inc.
</FONT>
<FONT SIZE="2">
<BR>__________________________________________<BR>
	(Exact name of registrant as specified in its charter)
</FONT>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM">
<TD WIDTH="33%">
	&nbsp;
</TD>
<TD WIDTH="34%">
	&nbsp;
</TD>
<TD WIDTH="33%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Tennessee
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	001-33637
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	62-1765329
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
_____________________<BR>
	(State or other jurisdiction
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
_____________<BR>
	(Commission
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
______________<BR>
	(I.R.S. Employer
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	of incorporation)
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	File Number)
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Identification No.)
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	2525 West End Avenue, Suite 950, Nashville, Tennessee
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	37203
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
_________________________________<BR>
	(Address of principal executive offices)
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
___________<BR>
	(Zip Code)
</FONT>
</TD>
</TR>
</TABLE>
</CENTER>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">

<TR VALIGN="BOTTOM">
<TD WIDTH="51%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="44%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Registrant&#146;s telephone number, including area code:
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	(615) 255-0068
</FONT>
</TD>
</TR>
</TABLE>
</CENTER>
<P ALIGN="CENTER">
<FONT SIZE="2">
	Not Applicable
<BR>______________________________________________<BR>
	Former name or former address, if changed since last report
</FONT>
<P ALIGN="CENTER">
<FONT SIZE="2">
	&nbsp;
</FONT>
<!-- CoverPageRegistrant END --><P><FONT SIZE="2">
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions:</FONT>
</P>
<P><FONT SIZE="2">
[&nbsp;&nbsp;]&nbsp;&nbsp;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<br>
[&nbsp;&nbsp;]&nbsp;&nbsp;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<br>
[&nbsp;&nbsp;]&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<br>
[&nbsp;&nbsp;]&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<br>
</P></FONT><!-- PageBreak START -->
<P>
<HR NOSHADE>
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
<A HREF="#DOCUMENT_TOP">
<U>
<B>
<FONT SIZE="2">Top of the Form</FONT>
</B>
</U>
</A>
</DIV>
<!-- PageBreak END --><!-- Item START -->
<P ALIGN="LEFT">
<FONT SIZE="2">
<B>
	Item 5.07 Submission of Matters to a Vote of Security Holders.
</B>
</FONT>
</P>
<P ALIGN="LEFT">
<FONT SIZE="2">
On April 19, 2011, the annual meeting of shareholders of Cumberland Pharmaceuticals Inc. (the "Company") was held in Nashville, Tennessee.  The following matters were voted upon and approved by the Company's shareholders:<br><br>(1) the election of three members to the Board of Directors;<br><br>(2) the ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2011; and<br><br>(3) all the compensation of the Company's named executive officers.<br><br>In adddition, the shareholders voted on the frequency of the "say on pay" vote, with 4,152,850 votes for every year, 154,195 votes for every other year, 8,247,882 votes for every three years, 42,136 votes abstained and 5,777,872 broker non-votes.  Therefore, based on the votes set forth above, the choice of the shareholders with respect to the frequency with which shareholders of the Company should be entitled to have an advisory vote on executive compensation was every three years.  In accordance with the results of the vote, the Board of Directors will follow the shareholders recommendation and the Company expects to conduct a vote on executive compensation every three years.<br><br>At the meeting, Joey Jacobs (12,374,537 votes for, 222,526 votes withheld and 5,777,872 broker non-votes), Jonathan Griggs (12,409,455 votes for, 187,608 votes withheld and 5,777,872 broker non-votes) and Dr. Robert G. Edwards (11,204,063 votes for, 1,393,000 votes withheld and 5,777,872 broker non-votes) were each elected to serve as a member of the Board of Directors until the 2014 annual meeting of shareholders. <br><br>The shareholders ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm (18,238,704 votes for, 132,834 votes against and 3,397 votes abstained).<br><br>The shareholders approved all the compensation of the Company's named executive officers, as disclosed pursuant to Item 402 of Regulation S-K (11,280,761 votes for, 869,286 votes against, 447,016 votes abstained and 5,777,872 broker non-votes).
</FONT>
</P>
<!-- Item END -->
<BR><BR><BR><BR><!-- Item START -->
<P ALIGN="LEFT">
<FONT SIZE="2">
<B>
	Item 8.01 Other Events.
</B>
</FONT>
</P>
<P ALIGN="LEFT">
<FONT SIZE="2">
On April 19, 2011, the Company issued a press release announcing the acquisition of the rights to Hepatoren&#x2122; (ifetroban) injection, a new Phase II development product.  A copy of the press release is furnished as Exhibit 99.1.
</FONT>
</P>
<!-- Item END -->
<BR><BR><BR><BR><!-- Item START -->
<P ALIGN="LEFT">
<FONT SIZE="2">
<B>
	Item 9.01 Financial Statements and Exhibits.
</B>
</FONT>
</P>
<P ALIGN="LEFT">
<FONT SIZE="2">
(d) Exhibits<br><br>99.1 Press release dated April 19, 2011
</FONT>
</P>
<!-- Item END -->
<BR><BR><BR><BR><P ALIGN="LEFT" STYLE="FONT-SIZE: 10PT"></P><!-- PageBreak START -->
<P>
<HR NOSHADE>
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
<A HREF="#DOCUMENT_TOP">
<U>
<B>
<FONT SIZE="2">Top of the Form</FONT>
</B>
</U>
</A>
</DIV>
<!-- PageBreak END --><!-- SignatureHeader START -->
<P ALIGN="CENTER">
<FONT SIZE="2">
<B>
	SIGNATURES
</B>
</FONT>
</P>
<P ALIGN="LEFT">
<FONT SIZE="2">
	Pursuant to the requirements of the Securities Exchange Act of 1934, the
	registrant has duly caused this report to be signed on its behalf by the
	undersigned hereunto duly authorized.
</FONT>
</P>
<!-- SignatureHeader END --><!-- Signature START -->
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM">
<TD WIDTH="19%">
	&nbsp;
</TD>
<TD WIDTH="34%">
	&nbsp;
</TD>
<TD WIDTH="3%">
	&nbsp;
</TD>
<TD WIDTH="1%">
	&nbsp;
</TD>
<TD WIDTH="43%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" VALIGN="TOP" ALIGN="LEFT">
<FONT SIZE="2">
	Cumberland Pharmaceuticals Inc.
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
<I>
	April 19, 2011
</I>
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	By:
</I>
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	A.J. Kazimi
</I>
<BR>
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<HR SIZE="1" NOSHADE>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	Name: A.J. Kazimi
</I>
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	Title: Chief Executive Officer
</I>
</FONT>
</TD>
</TR>
</TABLE>
</CENTER>
<!-- Signature END --><!-- PageBreak START -->
<P>
<HR NOSHADE>
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
<A HREF="#DOCUMENT_TOP">
<U>
<B>
<FONT SIZE="2">Top of the Form</FONT>
</B>
</U>
</A>
</DIV>
<!-- PageBreak END --><P ALIGN="CENTER">
<FONT SIZE="2">
	Exhibit&nbsp;Index
</FONT>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="60%">
<TR VALIGN="BOTTOM">
<TD WIDTH="8%">
	&nbsp;
</TD>
<TD WIDTH="15%">
	&nbsp;
</TD>
<TD WIDTH="77%">
	&nbsp;
</TD>
</TR>

<BR>
<TR VALIGN="BOTTOM">
<TD NOWRAP ALIGN="LEFT">
<FONT SIZE="1">
<B>
	Exhibit No.
</B>
</FONT>
</TD>
<TD>
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP ALIGN="LEFT">
<FONT SIZE="1">
<B>
	Description
</B>
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD NOWRAP ALIGN="CENTER">
<HR SIZE="1" NOSHADE>
</TD>
<TD>
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP ALIGN="CENTER">
<HR ALIGN="LEFT" SIZE="1" WIDTH="88%" NOSHADE>
</TD>
</TR>





<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" WIDTH="8%" nowrap>
<FONT SIZE="2">
<DIV ALIGN="LEFT">
	99.1
</DIV>
</FONT>
</TD>
<TD WIDTH="15%">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP" WIDTH="77%">
<FONT SIZE="2">
Press release dated April 19, 2011
</FONT>
</TD>
</TR></TABLE></CENTER><!-- HTMLFooter START -->
</BODY>
</HTML>
<!-- HTMLFooter END -->
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>
<HEAD>
<TITLE> EX-99.1 </TITLE>
</HEAD>
<BODY TEXT="#000000" BGCOLOR="#FFFFFF" ALINK="#0000FF" HLINK="#FF0000" VLINK="#800080">

<BODY style="font-family: 'Times New Roman',Times,serif">


<P align="left" style="font-size: 10pt"><FONT style="font-size: 12pt"><img src="e33307-1110915371718414b9_1.jpg">
</FONT>

<P align="center" style="font-size: 12pt"><B>CUMBERLAND PHARMACEUTICALS ANNOUNCES NEW PRODUCT</B>



<P align="center" style="font-size: 12pt"><B>ADDITION WITH HEPATOREN</B><sup><B>&#153;</sup> (IFETROBAN)&nbsp;INJECTION</B><BR>
<I>- Company acquires new hospital acute care product</I>



<P align="center" style="font-size: 12pt"><I>- FDA clears investigational new drug submission</I>



<P align="center" style="font-size: 12pt"><I>- Phase II clinical development program and manufacturing underway</I>



<P align="left" style="font-size: 12pt"><B>NASHVILLE, Tenn., (April&nbsp;19, 2011) &#151; Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)</B>,
<BR>
a specialty pharmaceutical company focused on hospital acute care and gastroenterology markets,
today announced that it has entered into an agreement to acquire the rights to ifetroban, a new
Phase II development product. The Company has initiated clinical development under the brand name
Hepatoren<sup>&#153;</sup> (ifetroban)&nbsp;Injection and is evaluating the product for the treatment of
critically ill hospitalized patients suffering from Hepatorenal Syndrome (HRS). Cumberland also
has commenced manufacturing and received clearance from the U.S. Food and Drug Administration (FDA)
for its investigational new drug (IND)&nbsp;submission associated with the product.


<P align="left" style="font-size: 12pt">Hepatorenal Syndrome is a life-threatening condition involving progressive kidney failure.
Approximately 450,000 patients in the United States suffer from medical conditions that make them
susceptible to cirrhosis and a subset of these patients develop HRS every year. Decrease in kidney
function causes nitrogen-containing waste products to build up in the bloodstream and ifetroban may
improve renal function in HRS patients by increasing low renal blood flow. There is currently no
drug approved for the treatment of HRS in the United States.


<P align="left" style="font-size: 12pt">Cumberland&#146;s acquisition of the ifetroban program includes rights to an extensive clinical database
and non-clinical data package as well as manufacturing processes, know-how and intellectual
property related to the product. Ifetroban, an active thromboxane receptor antagonist, was
initially developed by Bristol-Myers Squibb (BMS)&nbsp;for significant cardiovascular indications. BMS
conducted extensive preclinical and clinical studies, including seven Phase II trials for its own
target indications, and eventually donated the entire program to Vanderbilt University.
Researchers at Vanderbilt&#146;s Department of Clinical Pharmacology identified ifetroban as a
potentially valuable compound in treating patients for several niche indications.


<P align="left" style="font-size: 12pt">Cumberland Pharmaceuticals acquired the ifetroban program from Vanderbilt through its
majority-owned subsidiary, Cumberland Emerging Technologies (CET), assuming responsibility for
development and commercialization of the product. CET facilitated the program transfer, which
included product development activities at CET laboratories.


<P align="left" style="font-size: 12pt">&#147;This new product is an excellent strategic fit for our company given our established presence in
hospital acute care,&#148; said A.J. Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals.
&#147;CET was created in conjunction with Vanderbilt University to serve as a source of innovative new
biopharmaceutical products, and the ifetroban program represents a milestone for that organization.
Cumberland Pharmaceuticals is extremely pleased to have another opportunity to provide a potential
new solution to address an unmet medical need for critically ill patients.&#148;


<P align="left" style="font-size: 12pt">Cumberland plans to develop ifetroban for a series of indications, initially focusing on the
treatment of HRS for the hospital acute care market. In addition to commencing manufacturing, the
Company has initiated a Phase II clinical study for the product. Cumberland intends to develop
Hepatoren as an Orphan Drug for which the Company would pursue seven years of marketing
exclusivity. Patent applications have also been filed to protect certain intellectual property
related to the product.


<P align="left" style="font-size: 12pt"><B>About Ifetroban</B>


<P align="left" style="font-size: 12pt">Ifetroban is a pharmacological antagonist of the thromboxane A<sub>2</sub> / prostaglandin
endoperoxide receptor (TPR). Ifetroban exhibits high-affinity for TPRs on platelets, vascular
smooth muscle and certain other cell types and lacks agonistic activity. Ifetroban also displays
anti-platelet and anti-vasospastic activities and is effective in certain preclinical models of
vasospasm, thrombosis, reperfusion injury and endothelial dysfunction, including models that are
insensitive to aspirin.


<P align="left" style="font-size: 12pt"><B>About Cumberland Pharmaceuticals</B>


<P align="left" style="font-size: 12pt">Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the acquisition,
development and commercialization of branded prescription products. The Company&#146;s primary target
markets include hospital acute care and gastroenterology. Cumberland&#146;s marketed products include
Acetadote<sup>&#174;</sup> (<I>acetylcysteine</I>) Injection for the treatment of acetaminophen poisoning,
Caldolor<sup>&#174;</sup> (<I>ibuprofen</I>) Injection, the first injectable treatment for pain and fever
approved in the United States, and Kristalose<sup>&#174;</sup> (<I>lactulose</I>) for Oral Solution, a
prescription laxative. Cumberland is dedicated to providing innovative products that improve
quality of care for patients. For more information on Cumberland, please visit the Company&#146;s
website at <U>www.cumberlandpharma.com</U>.


<P align="left" style="font-size: 12pt"><B>About Cumberland Emerging Technologies</B>


<P align="left" style="font-size: 12pt">Cumberland Emerging Technologies, Inc. (CET)&nbsp;is a joint initiative between Vanderbilt University,
Cumberland Pharmaceuticals Inc. and the Tennessee Technology Development Corporation. The mission
of CET is to bring biomedical technologies and products conceived at research centers to the
commercial marketplace. CET helps manage the development and commercialization process for select
projects and provides expertise on intellectual property, regulatory, manufacturing and marketing
issues that are critical to successful new biomedical products. CET&#146;s Life Sciences Center,
located in Nashville, Tennessee, provides laboratory space, equipment and infrastructure for its
own product development activities as well as for other early-stage life sciences companies.


<P align="left" style="font-size: 12pt"><B>Forward-Looking Statements</B>


<P align="left" style="font-size: 12pt">This press release contains forward-looking statements, which are subject to certain risks and
reflect Cumberland&#146;s current views on future events based on what it believes are reasonable
assumptions. No assurance can be given that these events will occur. As with any business, all
phases of Cumberland&#146;s operations are subject to factors outside its control, and any one or
combination of these factors could materially affect Cumberland&#146;s results of operations. These
factors include market conditions, competition, an inability of manufacturers to produce
Cumberland&#146;s products on a timely basis or a failure of manufacturers to comply with regulations
applicable to pharmaceutical manufacturers, maintaining an effective sales and marketing
infrastructure and other factors discussed in the Company&#146;s 2010 Annual Report on Form 10-K filed
with the SEC on March&nbsp;11, 2011. There can be no assurance that results anticipated by the Company
will be realized or that they will have the expected effects. Readers are cautioned not to place
undue reliance on forward-looking statements, which speak only as of the date hereof. The Company
does not undertake any obligation to publicly revise these statements to reflect events after the
date hereof.

<DIV align="center">
<TABLE style="font-size: 12pt" cellspacing="0" border="0" cellpadding="0" width="95%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="60%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="font-size: 12pt">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Investor Contact:</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>Media Contact:</B></TD>
</TR>
<TR valign="bottom" style="font-size: 12pt">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Angela Novak<BR>
Corporate Relations<BR>
(615)&nbsp;255-0068<BR>
investors@cumberlandpharma.com
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Rebecca Kirkham<BR>
Lovell Communications<BR>
(615)&nbsp;297-7766<BR>
rebecca@lovell.com</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top" style="border-top: 1px solid #000000"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="left" style="font-size: 12pt">SOURCE: Cumberland Pharmaceuticals Inc.


<P align="center" style="font-size: 12pt"><FONT style="font-size: 11pt"># # #</FONT>




<P align="center" style="font-size: 10pt; display: none">




<!-- v.121908 -->
</BODY>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>e33307-1110915371718414b9_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 e33307-1110915371718414b9_1.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_
MVP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``1"`!=`9P#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#^^BBBB@`H
MHKQGQI\?OA5X$G>SUOQ5:S:A;W_]EZCINBVNJ>(M0T2^?P^WB>UA\26WA_3]
M4/A5-0T7R;K3[[Q4VB:9>M?Z5;V]])=:OID-W=.G4JRY*4)U)?RPBY/=+9)]
M6@NENTO5I?F>S5QE[\0/"FG^/O#GPPNM7MX?'/BSPGXS\=:!X?=+G[5J/A/X
M?:KX%T/Q?K4,BV[6@M]%UCXE^!K"XCEN8IY)?$$#6T4Z6]VT'XR?M(?\%I]`
M^%^C6[_#;X$^*==UN:#6HM03XC^)=`\)VVAW444T.BWD5IX0;XAKXGMI;U8[
MJ\T[^VO"LO\`9SHJZE%>O)!:_F5_P1S_`&P/CI^V?_P5]^*OQ'^.7B.SU34-
M)_8D^)6@^%?#FA:?_8W@_P`%>'F^//P&U+^Q/#.D-<7MTEL;R\FDFU'6M3UK
MQ%J"):Q:KK>H)8V0@^PP?!&;U,MS/.,;3AA,!E^`Q&*BY5:<Z^)JQCRTJ<*5
M-S<(*I*,ZDZDH>Y%QA&3FG'Q\;G%'"U\%AH)U*N+QM#"[-0IQG/WY.3WDHJ7
M*DFKV;=M_P"P.BD'0?0?RI:^,/8"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`KA/B7\3/`_P?\$Z]\1/B-XCT[PKX0\-VBW>
MJZQJ<DJPH9KF"QL;&TM[:&YO=3UG6-2N[/1_#^A:7:WFL^(==O\`3M"T6QO]
M6U&RLY^[K^5C]OC]I/X@_MF_M=7G[,OP8\*:YXO\&?`+Q?J&B)IOA32/&&KZ
MGXE^)NFRVO@KQYXO\0Z7<Z'IT.A:%\/-<U'4/A_I>O-8W/AZPTR3Q)XX/CFZ
M\)>.K6+1O>X>R.IGF-E1=58;!X6D\5C\7)QC"AAH2C%I3G:FJU64E3HJ;MS-
MS<7"G.W+BL2L/"+LY5*DE"G!)MRENW9)OEC%.4O1)-.2:_1&^_;/\6?M`>)[
M.V\&MK7@#X9P_P!DSVNG)/\`V7XZUG5-.UJ+6FO/$6OZ#JLZ66D2'3M'L3X1
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MME]W7K<_CL_:\^]>_6;_`-"K<_X-Q?\`E)U\7O\`LSCXD?\`JZ_V?*_JG\8?
M\$P?V(/B`_F^,/@U=ZO,3F1XOBI\9M'65L`%I+?0OB'IELS.!^\`A".6?Y`K
ME:_/C]LS]C+]G']@CX<:/\<?V/O`-]\!OBYXD\;:7\--<^('@WX@?$IO$FJ>
M`]6T'Q)XHU/PO=WFM>+]5#Z7?^(?!OA;5;J,)YD]UHEBTDC+&4;['$>(.3U.
M&\SR:&%S-XG&X&IAJ=25'"QHPJ2Y+.<EC)3Y/=WC!O5Z::^'BLDQ-?&X#$QJ
MT8PPF.I8JI%N?-*$'[T86A9RLW:[2;5FU>Z_H`'0?0?RI:_CRLO^"D?[:WA*
MSALM,^.>KWEK!*CLOB/PUX'\5W-PB2LS0W&J>)/#&IZNZ2@LLCKJ"3\AXYDD
M1'7ZT^%O_!=;QWHNJ6]E\>/@_P"'/$FA2WVGV\^O?"Z\OO#.N:5IB1R+J=_+
MX=\37OB'3?%.J2/Y,UK9V^O^![$-YL3S+'(C0?D!],?TLT5\Q?LX_MA?`']J
MC18=1^$GC>UO]973EU+5_`NL1OHOCKP_"L>F->-J7AV\VSW=CIMUJ]CI=WXC
MT&76O",FK2MIVG^(;ZXCD5?IV@`HHKX$_P""G/[:%U^P!^Q?\6_VGM*\(:?X
M]\1^"T\*:3X3\):MJ]SH>F:OXD\:>-/#O@VPDU"_M-.U*X-CH46NW7B>^T^&
M.SGUFQT.ZT6VU?1;K4(-6L^K!8/$YCC,+@,'3]KBL;B*.%P].ZCSUJ]2-.G'
MFDU&*<I*\IN,(K6<HQ3DN?%8JC@L-B,9B9JGA\+1JXBM-IODI48.I.5HIRDU
M&+M&*<I/2*;:1]]T5_('\,O^"G__``<@?&/X>^#?BI\-/^"=G[,'B[X?_$#P
M[I?BSP=XFM/#GBVUM=<\/:U:QWNF:G;V^H_M>65_##=VTL<L:7EI;W"J0)8D
M;(KH?$7_``42_P"#F'POH&M^)M>_X)L_LR:5H?A[2M0US6=3ET#Q))'I^DZ5
M:37^HWLD<7[84TKI;6EO+*ZQ122E5/EQR/A3]I+P\S6-:5"6;<*QK1JNC*D^
M),L52-6,U3E3=-UN=3C.\7#EYN96M=I'S:XQP$H1JPRWB*=*4%4C5CD&9NG*
MG*,9*I&:P_*X.+YE).S6M[-'];=%?DG_`,$9O^"COB7_`(*:?LH:M\9_'G@3
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M"A2O2DHRB_:5(QFI6<-;['[ZT4#D`^M?GA_P58_:S^(W[#?[!OQT_:C^$VC>
M"O$/C_X8#X9'0=&^(FFZYJW@Z]_X33XS?#GX=:J-8L/#?B+PGK<_V?1?%^I7
M>G_8?$&G^7JD%E-=?:[..>RN?'P.#KYCC<'E^%498G'8K#X+#QG)0C*OBJT*
M%&,IO2$74J13D](IMO1'IXO$TL%A<3C,0W&AA*%;$UI).3C2H4Y5:CC%:RDH
M1;45K)V74_0^BOSQ_P""4W[6/Q'_`&X_V"/@/^U)\6M'\%Z!\0?B@/B>-?TC
MX>:;KFD>#[3_`(0KXR_$3X>:6=(T[Q'XC\6:Q;FXT7PGIMUJ'VO7[\2ZI/?3
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M*#J?&WC/PS\.O!_BKQ_XUUO3?#/@WP1X=UKQ;XM\2:U=I8:/X?\`#7AS3KC5
M]=UO5;V0&.TT[2M+M+J_OKF3Y(+6WED;A37A2HUH5GAY4JD:\:CHRH2A)5HU
M5+D=)TVE-5%/W'!QYE+W;7T/8C4ISIJM&I"5&5-58U5*+INDX\ZJ*=^5P</>
M4KV<=;V.HHK^67_@F5_P7H^-'_!0W_@HWXG_`&>+3X9?##P=^S/<>'_BMXJ^
M'5_+H/BJ+XWRZ#X1ELD\)R^,]87XCZQX$BU35+.X^WZ_I>A^%3:Z9<7`TFPU
MK4DL#K&I?T'_`+7_`,6?$GP#_9/_`&F_CKX.L]%U'Q;\%_V?OC'\5_#&G>)+
M:]O?#NH>(?AW\//$/B[1K'7K33=0TC4;G1KO4-'M[;5(-/U73+^6QEN$L]1L
M;DQW,?MYKPSF^39IA,FS"C3I9AC:6"JTJ*K0FHK'3=.C&I./NPFIIQJ1;M%K
M>VIY67Y[EV9X#$YE@ZDZF$PT\3"=1TY1<OJJ;G*G&23E"25Z<M.96;Y;GT71
M7\8G[,W_``61_P""_O[8WP^O_BG^S5^PK^R5\4_`.E^*=1\$W_B+2]"\7Z/;
MVWBC2M,T;6+_`$EK7Q3^UUH>HO+;Z;X@TBZ:>.S>T=;U$BN))8YXXOH"Z_;K
M_P"#GRSMKB[G_P""97[,!BMH9)Y%@T_5+RX9(U+LL%I9_MFSW5U,P&V*VMH9
M;B>0K%#%)(RH??K>'>;X:M/#XC-.%\/B*4^2K0K\19;2K4Y^[>%2E4JQJ0FK
MZQE%25M4>32XSR[$4X5J&7\05J-6*G3K4LAS*I2J0E:TX5(4)0G%IW4HR<6M
MGJC^KNBOP+_X(@?\%<_BG_P4LL_C]X*^/GPM\%_#7XO_``&O?!D]]+X"C\4Z
M/X?\0Z-XRG\8V$MF?!_BV^\3:WX8UGP=J7A!;366O_&>J'5Y=?M_LNF:.=)O
M([CV#_@N!_P4+^-/_!-;]E7X=_'3X%^&OAAXJ\5^*_V@_#'PGU+3/BQHOBK7
M?#L7A[7?AQ\5?&%S?65KX0\:>!=3BUN'4_`FDP6UQ/J]S8+8W6I12Z;-<2VM
MU9^)/A7.:7$<>%:U&G3S>=>C0C3E6@Z$I8BC&O1G'$1YJ<J=2E.,XR3TORS4
M9*27I1XARR>1RX@A4J3RZ-&I6E-4JBJI4JLJ%6#HSC":G"M&5-II*\>9-Q:D
M_P!E**_D/\`_\%+_`/@Y+^*'@7P7\2_`7_!.+]F'Q)X&^(?A/P[XY\&>(K7P
M]XJ@M=?\*>+-(M->\.ZU;0WW[7]K>Q6^J:/?V=]`EW:V]RL5PJSP12!D'6_\
M-Z_\'.__`$C)_9H_\$?B#_Z,:O8EX?YE"4H3SGA.,X2<)QEQ-E2E&<6HRC).
MO=2C*Z:>J:L]6<$>+\%)1E'*^))1DHRC*/#^:-.,E%IIK#V::E=-:-6:W1_6
M'17SW^REXN^./CS]G7X0^,/VE?!6C?#GX\^(?!MAJ7Q2\#>'H)K71/"_BR62
M=;_2=+@N/$/BR=+2W5(C%YGB36BRN'%_,&!'\MFI_P#!;'_@L%\4OVW/VL_V
M1_V-_P!E;]EGXTS_`+.GQ8^-GARSM-2\-^.['Q0WPY^&'Q;O?AIIWB3Q#J6K
M_M+>"?#U[JMQ))H2:H-%L;&.:_OY)[+1K2Q5H[;R,GX6S'.Z^9T<'6RZ$<I3
MEC<5BL?0PV"A#V[PZJ1Q55QHRI2J+W*G,H2BXR3M)'=F'$."RRGE\\12QTIY
MGIA,/0P5>OBI25&->4)8:G%UHSA3;<X.'-%QDI)69_8O17\I9_;C_P"#H`<G
M_@F9^RT!QR8+SN<#_F]+UKUG_@C_`/\`!9C]J;]LO]KGXT?L9?MB?`GX;_";
MXG_#3P9XM\51S_#_`$WQMX1N-#UKX?\`B[PMX.\4^`/%OA#QCXE^(-Q<:I+<
M>*7U6S\06?B?1;&Q@T&YT]M(U=]9L]0LO0Q7`F<8?`8W,*6+R/,:.7THXC&0
MRS.\!CJ]##N48.M.C0JRFH1E))Z7>O*G9HY:'%N6U<5A<'5P^;8*KCJKHX5X
M_*<=@Z5:LH.?LH5:]&$7/E3=E?;6R:/Z6Z*_/'_@JM^UE\1OV'/V"_CK^U)\
M)M&\%^(/'_PO7X8G0=&^(>FZYJW@Z]_X3;XS?#GX=:I_;%AX;\1^$M;G^S:)
MXOU*ZT_[#XAT_P`O5(;*:Y^UVD<]C<K_`,$I_P!K'XC?MQ_L$_`?]J7XM:-X
M*\/_`!`^*'_"T!K^D?#S3M<TGP?:?\(3\9_B+\.]+.D:=XD\1^+-9M_M&B^$
MM-NK_P"UZ_?^;JD]]/;?9+26"QMOG_['QW]B_P!O\E/^S?[4>3>T]I'VOUY8
M18YP]C\7LUAY)^U;2YGRI-WMZ_\`:>$_M5Y,I3^O+`?VFX<C]FL)]8^JJ?M/
MAYW7]WV:N^7WGH?H;1117EGH!161K^O:+X6T35_$OB35=.T'P[X?TR_UK7M=
MUB]M]-TC1='TNUEO=3U75=1O)(;/3]-TZR@GO+Z_O)H;2SM89;FYFB@BDD7^
M/KX,_P#!S#\3O&?[:/@C2_B)\+?AAX)_X)V?%+X__$#X*>!OC7?:%XG\/?$"
MVM-$L]`BT3Q3XR\9^*/B98_#?2+?PU-\1?A1XR^,-F?"ML?`7@'QBTXO-5N[
M"TO-;]_)>&<XX@I9C6RO#*O#+,.\1B.:K"E*?N3J1H8>,VGB,34A2JRIT:=Y
MR5.5M58\?-,]RS)ZF"I8^O[*>/KJA12C*=KRIPE5JN*:I4(3JT83JS:BI58)
MO5M?V.445X/^U+\3-?\`@M^S/^T+\8_"=KI%[XI^$_P0^*_Q*\-V?B"VN[S0
MKO7O`W@/7O$^D6NM6FGW^E7]SI-Q?Z7;PZE;V.J:;>36;S1VM_9SM'<1^)2I
MSK5:=&"O.K4A3@F[)SG)1BFWHKMK5['JU)QI4YU)7Y81E.5M7:*N[+O9'O%%
M?RR?\$A/^#BW3?VROBG+^SI^V5H?PV^#/QC\;:W;6GP+\7>`K?7]!^%'CV]N
MX;.VM_A;JD'C'Q7XRU7PU\3M3U`S3^#+N[\22^'OB%+=Q^#-.M]!\;6_AC3/
MB1_4W7JY[P_FO#>/GEV;X9X?$1C&I!J2J4*]*6U7#UH^Y6IWO%R@WRSC*$K3
MBTO/RC.,OSS!PQV75U6HR;C)-.-6E4C\5.M2E:=*:TDHR2YH.,XWA*+917\\
M?_!0O_@K!^T;^RC_`,%5OV)_V'/ASX0^"^K_``F_:4;]FY/&_B'QGX;\;:E\
M1-&'Q>_:,\7_``D\4MX2U?1?B)X>\-63VOAG0[2\T,ZUX2U]+/6WGNKY-3L7
M338_Z'*RQ^48W+<-E>+Q481I9OA)8W!N%13E*C&K.BW-+X)<\'[KUMKLR\'F
M>%QV(S##8>4G5RS$QPN*4H2BHUI4H5DH-JTX^SG'WH];KI=E%?R<?MH?\%F/
M^"FGP]_X*=_%K_@GW^QC^SU^SA\:;[PM;^"KWP)I7C#POX]G\?:W:ZO\!_!?
MQB\5/J>L6OQW^'WA.8:,==UPVIM]+TIO['L;6"1+W4%DN+JMJ7_!0/\`X.<M
M-L+O4)_^"9/[.IM[*"2YG73O"GB[5KYHH1O=;73-,_:[OM1OYBH(2VL;.YN9
M6(2&)W*BOIH>'^<.A@J]?'\/8+^T,'A,?AJ..SW`83$2PN-IPJ8>HZ%>I"HE
M.,[7LXJ<9PYFXNWB/C'+/:XFG3PF=8E83%8C!UZV$R;'XG#QQ&%G[.O35:C1
MG3DX3WL[V<962DC^M"BOY,OV9O\`@Y!^)?@SXR>$?V?O^"JO[).M?LD>)_%Z
M6]S;?$V'P[\0/AQH>CVNO:O#HOA;5/%?P@^+UI<>+-%\`3W5GXE_M;XGZ?\`
M$'Q#;65QI]M%_P`(F=+36M>TC^D/]H7XV:S\)],^&FE>!O".G^/_`(F?&OXF
M:=\*?A=X8UGQ+-X+\-W^O_\`",^*_B/XJU/Q%XMB\.^*GT32?"/PE^'7Q)\=
MNL6@W][XAG\*V_A+1HCK?B'3"/%S7AC.LEQ.&PN/PL(O&TY5\'B*.(P^(P6*
MH4[NI7HXVC4GAW2HQ7/7<YPEAZ=IUXTXM,]/+L^RO-</7Q&#Q$I_59QI8JA4
MHUJ.+PU:7PT:V%K0A7C4F[QIKD:K235)S>A]%45^6'[!7[?/BW]J;7KKP[XC
M\&0WNB:A:?$#4/!OQ>\,Z;X,\/>$M>F^&"?!NX\9Z"^A^!_CW^T]X3NH;./X
M]^!=+T#Q?X3^.GBR76/&_A3X\>`O'W@/X,^(OA%IMO\`$C]3Z\O'8#$Y=B)8
M;%04*L5?W9*<91YI133B]'>,E*,K3A).,XIH]#"XJCC*4:U%MPE;XHRBUS1C
M-)II:N,HRNKQ::<9---\1\3+OQS8?#KQU??#'1-&\2_$BQ\(>([WX?\`AWQ%
MJ;:)X?USQM::3=W'A72-<UA(+I])T?4==CL;34M3CMKB6PLY9KJ."9XEC;PC
M]CW]CSX1?L7_``DT/X9_#'0],&JIH^BVWCWX@+I,-CXF^)6OZ5%=M)K_`(BN
M3/?WIA%]J>KW&AZ"^I7FF^&+74I]-T@1P-*TWT=XLA\27'A;Q);^#;W2]-\7
MW&A:M!X5U+7+.;4-$T_Q'-83QZ)?:Q86\]K<7VE6FIM;7&HV=O<V\]S9QS0P
MSQ2NLB\W\-OB?X1^*'A[3M;\,ZWHFHS7.D:5JM_8:5J]OJK:<FK13-:N9(T@
MFGTZ[EM+Y=(U5K.VM]8M[26[M$V+(L><,57IX:M@X5'##XBK2JXB$6U[>=!3
M5!5=??A0]I5E2@U:,ZLYN\N5QT=*#J1JN*<X1E"#>O*IM.;CV<^6*DUO&*7>
M_HE%%%<YH%?F5_P59\"^-_B%^SOX2T3P#X-\5>.-:M_C#X?U.XTCP?X>U?Q-
MJD&FP^#/']G-J,VGZ+9WMW'8PW=_96TUV\(MXI[RVB>17GB5OTUHH`_B"\0_
MLP_M+6UK)=7'[._QU@M45Y'N9OA%\0(H$C3<[NTS^'EC5%4$LQ8*`&R?E./C
M7Q39W>GWMUI]_:W-C?VDKQW=C>02VUY:2*(]T=U;3*D]O(/.BS',B.-Z_+S7
M^B/56]L;/4K2YT_4;6WOK&\ADMKNSNX8[BUNK>52LD-Q;RJ\4T4BDJT<BLK#
MJ*`/X2/V?]2U/1M1T75M%U/4M%U;3IX;O3M6T?4+S2M4T^[B;=%=6&HZ?/;W
MEE=1'F*YMIXIHF^:-U/-?UC_`+'/[5^H_&"QM/!?Q!CMD\<V^G>;8:[8VT%E
M9^*ELH&DO!<:=;[(;+7Q;0RZG<1Z=;PZ1=PI?2V=II*6L=E+W_B_]@[]DKQ?
M!`H^!_@?P=>V<&H1:?J?PVTF'X<W-I/J**LE_-;>#1HVDZW>6LBBXL?^$FTW
M6[2VN#(WV22*YO(;CYB\1?L0ZY\(OMOB+X<ZYJ_C?PMI$8U6/1Y!<V?Q0TK^
MS!X?:WET.Y\+VUG%XIU>&[7Q'XCBN]`A\'^(M.73]!T7PMH7B7Q%,NH.`?JQ
M7\]O_!SG_P`HK?&?_98O@]_ZD%Q7[H_"OQ?<>._A_P"&?%-ZD2WVI6!^W/;V
M]O:6-W>6L\MG/J>EVEOK?B+[+HNL-!_:^A6]UK-YJ<6BWVGKJPMM3^UVL'XC
M_P#!R_H.HZQ_P2A^*VH64:O:^%?B/\&-?UAV+#R=/N/B%H_A:%TPC*7;5O$N
MEQ;7>,;)'8,S*$;ZO@62CQEPPY-)?VWET;MVUEB81BO64FDEU;21\[Q;&4N&
M,_44V_[)QKLM[*A-OY))M^5S[O\`^"37_*,W]A3_`+-?^#__`*AVF5]V^*/#
M6B^,_#>O^$/$EF=1\.^*=%U7P[KVG"YN[+[?HVMV,^FZG9?:]/GM;^V^U6=S
M-"9[.ZM[F(/YD$T4JHZ_S3?\$]?^"Z/_``2T^!?[#?[)_P`'?BC^TY-X9^(W
MPT^`_P`-_!GC;P]_PI/]H36O[%\2Z#X:L+'5M,.K>'?A3J^A:B;2ZBDA-YI&
MJ:AITY0O:7EQ"5E;Z.^)W_!Q'_P2HD^&_P`0%^'?[7$A^(!\%>*3X%#?`']H
MI1_PF2Z'?MX7(;6_@N=&5AKBV.QM7']EJ^TZ@RVGFL/2SGA'BNOQ!F=7#\.Y
M]R5<WQCHXB.4YA[-*6,FH5E5CA](1;4_:Q=HQ7M(MI)G-E_$G#E/*L#&IGF3
M<U/+<*JE&69X'GYH86GSTW3E73YTURN$DGS>ZU<_3O\`9)_8C_9B_87\%^)/
MAY^RS\,A\+?!WBWQ.?&7B#1QXS^(7C8:AXE;2M/T1M3.H?$7Q7XNU2U)TO2M
M/M?LEE>VU@!;B7[+Y\DLLG\RG_!;/_E.S_P1P_[*%^R]_P"M?VU?H[_P;O\`
M[8_[4O[</[)WQB^+G[5/Q,7XH^*-!_:)U?X=>&M8'A'P!X+?3]"T;X9_#/Q+
M-IATGX>>%/"6E3QK?^,);J/4+NQN+Z9[F:V>Z\FTABC_`#._X.!M;TGX*_\`
M!6;_`()+?M(_$J\;P[\'?!WB[X7ZUXE\5KI^JZM_9FE_!G]I#PKX\^(MV-*T
M6PU#5M2_L#PKXIT75&L=&LM1U>]6Y^S6&FW-X]K;W7O\,8#,,N\0\SRO,\:L
MSS6&69]AJN)IXC$XV>,Q,LEK34:=7$PABJ]11:A:=-3O!I*R1X7$&+P.+X(P
MN-P&'6!R^KB,HK4:$J='#PP]%YKA?BA1E*A1@G>3<9^S2?,W;4_LK'0?0?RK
M\4?^#B3_`)0]_M=_[GP$_P#6I/@=2#_@XF_X(\#C_AKF;CC_`)-__:>_^<Q7
MY??\%F?^"S?_``3:_:Q_X)N_M&?`+X`_M%OX[^+7CP?"(>%/"C_!_P"._A8:
MK_PC'QZ^%GC773_;OC+X8>'_``W8BP\->&M8U$C4=8LS=?919V0N;^XMK6;P
M^%^%.*,-Q-PYB,1PYGM##T,^R:M7K5<IQ].E1HTLQPM2I5J3EAU&%.G!.<YR
M:C&*;;23/5X@XAR"OD.=4:.>9/6K5LIS"G2I4LSP4ZE6I4PE6,*=.$:[E.<Y
M2C&,8IRE)I)-M'ZB_P#!NW_RAU_9`_[K_P#^M0_&NOR)_P""RW@#PG\6?^"]
MG_!.3X5>/M+;7/`?Q/\`@IX0^'/CC0UO]1TLZWX,\<_$KX\>%O%6C'4M(N[#
M5;!-6T'5=0T^2[TV^L[ZW2Y:2UN8)U21?U^_X-Y;2[L?^"/?['T%[:W-G*\'
MQUNXXKN":VEDL[_]ICXRWVGWBQ3(CFVO["YMKZRG`,5W97,%U;O)!-'(WY9_
M\%4/^5B__@E+_P!B7\(__5U?&BO:RNI*GXA\;5:4W&<:7'LZ=2G*SB_8YE*$
MX3CLU=2C*+NG9IIH\K,8)\$<*4ZD4TY\&0G":337M,OC.$XO3O&46NZ:W15_
MX)N?%7XF?\$;?^"@?B3_`())?M-^)-8UO]FOX\^(_P#A+OV)/B5?7&FZGIEC
MJOC;6;^U\,Z=<RI!INHZ)'\3;^TE\$^+?#-E:R:=X<^/>CQZCX;\.OX5^)NL
M_$;4/6?^"UGQO^*_[<?[1_PK_P"")O[(]U=OX@^(%]X3^('[8WCBWT?3[_2?
MAE\,+271O&&B:=K-Y=ZI8R6UAH6EOIGQ7\86!.A7OB2Y?X-^`O"/B34M6\=Z
M[X4N/U&_X*^_\$U/#'_!2G]ES5/`5@N@Z#\?/AW+>^-/V??B!JUA'(='\6B"
MV75_!&K:K%Y>JZ=X&^)^GZ?:Z!XH-G-/:Z9JEGX3\=W6@^)K[P)I.BW7B?\`
MP11_X)B^*?V(OAAXU^-?[3;VWB[]NC]I;7-1\7_&GQCJ6K1^,O$7@[1M3U*;
M6+;X:MXY&IZO::_K&H:U/=>./BGXCT&Y6P\5^-M1L]-GU+QCI7P^\(>*KS%9
M[D-6G#CBM*B^+,-26$J9/[.*I8W/E&,<)Q,XQ:C]7IX=5,3BZ,8P3S2E0490
MC7YI]#RC-H3J<*4U57#M:;Q$,R4FZN&RAROB<A<I*[K3KRC0P]5RDXY;6K/W
MIT%"'XZ_L)_`?X>?LP?\'+7Q-_9]^%&FMI?P_P#A+^RWX,\&^'HYX=,CU/48
MM-_90_9Y^W^(_$$FC:;H^FW_`(K\5:M)J'B?Q=K%KI=@NN>)]8U;6)+6&:^D
M6OZ=_P#@I;_RCF_;Y_[,O_:@_P#5)>-Z_GM^#7_*V5^T_P#]D-T3_P!97_9Z
MK^A+_@I;_P`HYOV^?^S+_P!J#_U27C>CBBK4K\4<!UZTY5:U?AS@>M6JS;E.
MI5JJ-2I4G)ZRG.<I2DWJVVQ9!3A2R/BJE3A&%.GG'$L*<(I1C"$*]>,81BM(
MQC%)12T222T/XN?^"+__``51_:5_8F_92\6?"7X0?\$U/C;^V!X8UGXY>+?'
MMU\3_AUK7CO3]"TO6-7\%_#K0KGP7-;^&?@#\3[`ZEI=KX8LM7GFE\1V]T]O
MK]HKZ3;11Q75[^L>I_\`!Q-^VOH>FW^M:W_P0Z_:=TC1M)L[G4M6U74_&7Q5
ML--TW3K*%[F\O[^_NOV/H[:RLK2VBEN+JZN)(X+>"-Y972-&8?('_!OI_P`%
M7/V!?V'_`-BCQU\(_P!J'X\GX8?$'6?VC_&_C[3?#W_"K?C1XU^T>%-8^'WP
MIT/3]5_M7X=_#KQ;H<7VC5/#6M6QL9]3BU.'[&)KBRBM[FTFN/W/?_@XD_X(
M[JN4_:]+ME1M_P"&?_VHUX+`,<GX(X^526QWQ@<FOIN*\'"?$N<2EX49CG//
MCZLGFE*MQ5"./4G%_6(?5&\+%5%;^"O8I-M+E=CY[(,14ADN5I>(V!RQ0P6'
MBLOK4<@=7!\M."^KSEB)QKN5)KD;JQ51O65V[GY7_P#!JQX+7Q7+^W-^U5J7
MCWX=7_B;XM>-_!VEZI\*_"6MWLOB_P"'\_\`;7Q*\7:EJWC7POJNF+=Z-X;\
M6W/B"TB^&.L6FOZY::W%X;\;6-U<C5?#][!;>]_\'97_`"CM^"O_`&>E\/?_
M`%1O[15?$/\`P;*^)V^)O[>O_!2KXJ?#O1]1\._!+Q@/^$IL?#;B"TM?#S^/
M/C!XV\1_"C2-2TVRFN;&#5-,\'P>-].L5@GN+>TAM]8@L[B6&0M)]O?\'97_
M`"CM^"O_`&>E\/?_`%1O[15<^+IU*7C5EBJ2O*6*R6:I6C&6$IO*<.J6#J**
M2<\-!*GSM<U1152?O29TT90EX6XWDA:,*&94_:7;CB91S.MSXN+;=HXB;E5Y
M4W&$I.$7RQBSXD_95_X.#OVC/@I^R_\`LX?!O0/^"3/QF^(VB?"?X#_"+X:Z
M/\0=*^)/CJRTSQUIG@;P!X>\,V7C+3;&U_9A\06MGI_BBVTR+7+.TM]?UR"V
MMKZ*&'6-3C1;V?\`I%_X)D_MR>/OV_?@7XP^,'Q$_9G\5_LK:SX9^+6M_#:U
M^'OC#Q#JOB34]6TS2/!O@3Q/%XPAO-9^'7PSO+>RU"[\87NC167]A7D23Z!<
MW":O,;EK+3_S&_8:_P""[?\`P2H^#O[%?[(?PD^(W[4W_"._$'X7?LQ?`?X>
M>.M`'P/_`&CM8_L3QCX,^%OA3P[XETC^U=!^$&J:)J?]FZSIM[9?VAH^IZCI
M=[Y'VC3[ZZM)(IW^IO\`B(C_`.".O_1WY_\`$?OVI/\`YR5>#Q)E&)QSQE++
M/"_.LMQ;QU2:S2BN(\=[:FJL^=QP^(H2PZCB4XS4H?`FE3;B]?7R/,J&$6%J
M8_C_`"G'8=82G'ZA/^PL)[.;I4U%.O0JJOS4/A:D[S?QZZ'[5U_GY?L7_MY_
ML]?\$^/^"V__``5)^+7[1^K>)M(\'^+/BE^U[\/-&G\+>&+[Q5?2>)+[]K6R
M\2P13V-@Z2V]I_9GAG4V>[8F-9EAB(S**_NG_9\_:"^$7[4_PA\'?'GX$>+?
M^$Z^$_C^'5[CPCXK_L'Q-X9_M:+0?$.K^%=6;^P_&.B^'O$EA]DU[0M4L-NI
MZ/9O/]E^U6RS64UM<S?QH?\`!*SX%_!+X^_\%Y?^"KWA;X[?!WX6?&KPQI'C
M']L3Q#I/ASXM?#[PE\1M"TOQ!#^V+H&EPZYIVD^,-(UBPL=8BTW5-2T^/4K6
M"*]2QU"^M%G%O=W$<F?`\,/A,LX_IYQA,:Z%#*,-3QV#HR6#QT90S&,)4E+$
M4JBH5J=5)3C5I-QY90<5+:^+)5Z^:<%SRZOAE6JX_&5,)7K1EB,+)3RV4X3:
MHU(.I"<'>#A4BGS1ES<MS]A3_P`'.'_!*U4ROC7XQR$`85?@YXA!;V!>=%'_
M``)A7Y&_\$4/C#I7[6O_``7J_;._:@^'&@>([+X:>-OA3\7?$^G3^(;."TU'
M3M&U?Q]\)-&\-)KB6-Q?Z?8:SK,6GR7D>D0ZC>R1)#J"PW%]%IEW=C[S_P""
MQ_\`P0H^&_Q+^'VC_M(?L"?!;X6?"S]H'X%VD.MR?!SP%\+?`FF?#+XY>%_#
MU]+X@_L*\^$]OX;F\!^(/B)8W;3SZ0FJ>&-0LOB/I3W7PZ\;6/B"QF\(_P#"
M-_0'_!"3_@I#^RM^U!\)KKX&>$/A!\'_`-D_]ISP5]JUCXK?`7X7^!?#OPM\
M)>.-0M1!I6K?%?X?^'M#TO28+ZVO!9V5OXJT6[6\\4^";Z.'2=5GU'15T#Q!
MJWJTWP[@N#\[S7A'+LUQ=3,L!4R7.Z>.S'#UJV0TJU>E6AB:V%H8*E*OAJ_L
M(NCBZ=3V*FG3K>RE&<'Q3_MG%<1Y9E_$>-P&%IX+&1S+*IX7`UH4\XG3I2I.
MC2Q%7%5(TJ]'VLW5PU2"J\O+.G[6,XM>Q_\`!Q%_RAX_:^_W?@#_`.M2?!"E
M_P"#=S_E#K^R!]?V@?\`UJ3XVTG_``<1?\H>/VOO]WX`_P#K4GP0K\O/^",W
M_!9W_@FW^R=_P39_9P^`'Q__`&BG\"?%KP%_PN`^+/"J?"'X[>*ETK_A*OCU
M\4?&NA#^W?!OPQ\0>'+[[;X:\2:-J/\`Q+M7N_LWVLVEW]GO[>ZM8/*P&69E
MFOA;*AEF7XW,:\/$"I5G1P.%KXNK"DN',/3=2<*$*DHP4ZD(.;2CS3BKW:.S
M%8_`Y?X@NMC\;A,#2J<'0I0JXS$T<-3G5EG4IJG&=:<(RFX4YR44V^6,G:R/
MZ[Z*_$__`(B)_P#@CQ_T=Q-_XC_^T]_\YBOT;^%?[7W[._QJ_9JB_:_^''Q)
MT[5_V<I?#7CWQB?B?J^E>)/!6CVGACX8:MXET3QYKNJ:?XYT3PWXBT;3/#>H
M>#_$BWMUJ^BV2/:Z7+J-K]HTZ:VNYOAL;P_GN6PI5,QR7-L!3KUHX>C/&9?B
M\-"K7FG*%&G*M1@IU913DJ<6YN,92M:,FOKL+G.48Z<Z>"S7+L9.G3=6I#"8
MW#8B5.E%I.I.-&K-P@G**YY)1YI15[R2?XB_\'&7[9GBSP/\$?AY_P`$_?V?
MVN-:_:6_;L\1Z;\.X_#WA_5+"+Q':_";5=<T_P`.7^DE8O%&DZGH=Y\;/%^H
MZ5\+=!EUS1-2\'>+_""?&;29K[3]3T.*6+7_`&N/^"*/A34?^"+WA?\`8M^%
MNEV6O?'#]FKPO%\7/AWXBT^U=+SXB_'RQAU36_BA;P->7EM>+:?&9M=\8^&_
M#.C:OK*:/X9N]2\`-?R2:;X#TV.#\7OV>/V5/VG?^"_7[7_[3W_!0WPK^TIX
MY_9`\&_"_P"(NB?#S]G#QKI?AWQ!K_BCP_H>D:3?/HG@3PL=$^,?ABZ\!>)/
M"G@;4?#OC'XFW?AKQ$^@:M\0?BOKFK>'K2*#6]2%M^I?_#BG_@I1_P!)_?VQ
M/_,[?_1@U^K3H97PQAN'LF_UOR_(\WR7&PSS.\/7P&;8F=;.ZT*,J5"K5P>#
MJ4)8?`X":P7LZ=>:DZ^,E-1E4LOSR-7,,]KYSF+X;QF;Y9FF'EE>4UX8W+,-
M&GE-.<HSK4Z6+Q,*JJXO&7Q2JSI1O&EAG!RC",I?7W_!`#_@H,_[<W[$6@Z#
MXXUN?5OCY^S6FA?"CXJW6HW=_J&L^+-%73[D_"[XI:EJ&JZMKFKZM?>./#.D
MW6G>*-?UF_2_\0?$CPAX\U<6-CI][IT)_17_`(*!?\F(?MJ?]FG?M%?^J@\8
M5_&%9_#?XL?\&XW_``5%^`?C[XG_`!HU/XY?L_\`[4WAS7M#^,GQ<U#PS>^'
M)_$&AZUXMT^'XHZEJVB2ZM\8/%FI^+/@MK^J_#KXR7NIZ5)+XB\>:=JDO@K2
M]1M9?$_B,)_9M^WS<07?[!'[9MU:RQSV\_[)7[0\L$T+!XI8G^#_`(P9)(G4
ME7C=2&1U)5E(*D@@U\QQ=E&!P/$N69MDLZ=;A[B+$4<RRJO0C4CAX3^MQIX[
M!056%.I!X7%*3A2J4X3AAZM"#7/&=OH.'<RQ>+R3&9?FD)T<XR6F\#F%*K*,
MZLH^PYL'BIRA*<)?6<.ES3C4G&=6G5E&3BXG\4O_``2Z_P""0GPV_P""G?\`
MP2<^+VJ:1<Z+\._VJ_AC^UK\3;3X-?%JZM)5TW5+)_@U^SWJA^%WQ6;3K>?4
MM7^'.I:A<:A=Z1J=O::EXA^%_B/5;[Q=X2L=4L=2\<>!?B#^NG_!'_\`X+!_
M$_PY\4)/^"7/_!4B/6OAS^UE\.]:M?AS\,/B;\1KJW74/B;?^3"WAKX7?$W7
MX[B[TO5OB?K&DW.E7OPC^+%GJFI>'OVC_#VJ:"HUS5?B7JWAOQ%\<>E_X--?
M^4=WQK_[/1^(/_JCOV=Z^Y_^"P/_``1]^%O_``4[^%T6K:5+H7PZ_:N^'FBW
M=I\(OB_=VEPNFZUIPEN+_P#X5+\6_P"RX;C4M8^&6KW]U?7.F:G;6>I>(_A;
MXBU.^\6^$+34].U;Q_X"^(_T?$>>Y?B^)^(>%^*7.632S;$/*\TA'GQG#F*J
MNE>K1N^>O@*TO][P5^62_>4TJL8M_/Y!E>-P_#^2Y_D"@LR6748X_+YR<,+G
M>'IW4:52VE+&THZ87%;W2I5FZ;O#\1O^"TW_`"L0_P#!*'_KK^PY_P"MN_$B
MO[5:_P`QG0?BY^UY\0?^"L__``39^&W[<^GZ_:_M&?LM?M%_LE_LY:]?^,K=
M?^$[U[PCX<_:3TGQSX*UCQSX@AU/5=/^(6NSZ;\0IX=+^*NDW-Q8?$_P/!X/
M\;3ZQXQUK6=8\>^*O].:O&\1<OJ95@>"LOJ5J&(EALBKP6(PU15</7IO,*TZ
M5>A46DZ5:E*%6G+1\LU=)GK<$XR&88WBS&4Z=:C'$9OAYNCB(.G7H5%EV'C5
MH5H/X:E&K&=*5KQ;AS1;BTW_`!B>$_\`E;R\7?\`8L6O_KN_PI7]G=?PG_&7
M]I7X*?LB_P#!TG\4?CS^T)XS/@#X5>$M"\+V7B#Q0/#GBOQ6;"X\3?L%>!?#
M>BQC0_!6A^(_$5U]LUK5+"RW6>D7$=L+@W-V]O:Q2S)_0!_Q$3_\$><@#]KE
M\9`8M\`?VH!@%@"1M^"C[L`EB#M^53@EB%/3QOP_GV9RX2Q66Y+FV889<"\-
M4GB,%EV+Q5%58X:3E3=2A1J0]I%3BY0OS)2BVDI*^'"N<Y/@(\04<=FN6X.L
M^*L]FJ.*QV%P];DEBDHS]E5JPGR2::C+EY6TTF[.WD'_``<P_`SX;?$?_@F%
M\2/BQXHT&"Y^('[.WBOX:>,/A=XFAALDU71KKQ_\5OAY\)O&&BR:C)9S:D?"
M_B'PUXPDO=7T"SO;*PU/Q)X:\%ZUJ,=U<^&=,$7J/_!)C3IOVRO^".W[$VH?
M$75+SPQXV\%>%M3T#X8_$OX>K9Z3XW^%NK_L_P#Q!^(7P.^&GCOP9?ZU:>(=
M.7Q5#\/?"5MH/C*SU_2]=\%?$SP_K_CCP%\1O"/BKX8^._%_@?6OP<_X*U?\
M%@(?^"K=EX6_X)K_`/!-KX<?%;XH3?%7XFZ';^)/%$N@:3H$/QBT_P`(W:^)
M]%T+P?X>\1H?$?A_P%IVO:7I/Q+\7_$3Q_)\*)/!NE>`);WQ59V/@H>(]4MO
MZY?V"/V8-._8Q_8[_9\_9EL18O=_"KX>Z?IOBN]TJ^U/4=(UCXC:Y=WOBSXH
M^(=&N-86+45T7Q)\1]?\5:_H]I/;60T_3=2M=/AT_3H+6*QM^?.</C.'^`LC
MRO-E+"9Y/B7%9UE^"K-+&X#*98"&&E[6B[U,+#$XU2K*A5455;E-P<XU%'IR
MRKA\YXNS7,,N<<3D\<AH97C,52_W7%YDL;*M'V556CB)4,(_9RJTY/V:E%*5
MG!O-^!7[$O@/X'_%/Q#\93X[^(WQ*\>ZSH4WAK3-0\;_`/"OM'TSPCHVI^&/
M@]X0\50Z!X>^%?@#X;Z'=7GC30_V?/@E#X@U/Q38^)+^TE^'6F#PC/X6LM6\
M36.M_9U%%?FN)Q5?%U/:XBK*K44(4TY62C"FN6$(1BE"$4M;1BKR<IRO*4F_
MN*-&E0AR48*$7)R=KMRD[)RE*3<I.R2O)MV26R05^0/[7'ASQ?\``CQ__P`+
M*\&^*=5T6'QMKU[?Z'J.EOXBM;O3-5,ND^*M?\):QKM]JFI6NN67B36],U#Q
M-;>%6EL=!OO#6GS>'/\`A$+G0O!EU=77Z_5RWC7P5X7^(OA;6?!?C/1K/7_#
M6OV@L]4TR]$H26-9X;J">VN+>6"]T[4K"\MK;4-(UC3;FSU;1M5M+/5=*O;/
M4;.VN8L#4_!.P_X*X_%[X7Q26?Q!\`^%_BM96FG306U[9:A)\/?%5UJ8NWEB
MOM5U.STOQ#X7FMDM&6S^Q:;X)TER4CNVNY7$L,_M_A3_`(+F_LL:S-IUAXD\
M!?&OPGJ$Y@AU.Z.A>$==\-Z7<%$^U.NH:?XSC\07^GP2F417$/A*.^N(424Z
M7!+(;>+Y-_;;_P"";'Q;\"V]YXH^#EEK7Q?\$+;QR7%C8VD5W\2-(N)KZ"P%
MO/X;TFW1_%5N_P!JL[K^U/"^GK/$/[8GU+PYHFD:3%J-[_/U;_\`(1GR"#Y\
MN0P*D<MU#`$'ZB@#^U2T_P""J7["%VJ%/C?,C,N2C_"_XPL4;GY28O`$B<*I
M9FWX"X(S\VWV?X*?MG?LV_M$^*;WP7\'?B'<>+_$FG:%<^)KVP;P-\1?#D<&
MB6=YI>GW-Z=1\5^$M#TQS%>ZUIEN;6.\>\+W/RV[+#<-%_$?HO5/\_Q"OVU_
MX(Q_\G*^/?\`LA7B;_U8/PPH`_I=HHHH`***^(/VL_\`@H!^SU^R-X=U6Y\9
M>)X?$_CVTA@-A\*/!UQ::KXYN;B\&FRVK:Q:&>*R\'Z:UAJD.M?VEXLN])6^
MTB"Z?PY;>(=46UT>\Z<)@\7C\13PN"P];%8BJU&%*C"4Y.[2N[*T8J_O3DXQ
MBM9-+4B=2%*+G4DH0CO*3LN]EW;MI%7<GHDV?7/AWP?X=\)W'B>Y\/Z9;:6W
MC#Q+<^+M=BLX(+6WNO$%[INEZ;J&I&"WBB3[7J2Z3!>:C<N)+B^U&:ZO;F:2
M:=C1XR\%^$?B)X6U[P-X^\,>'_&O@OQ5I=WHGB?PEXKT;3_$/AKQ%HU_'Y-[
MI.N:'JUO=Z;JNFW<1:*ZL;ZVGMIXR4EC920?CW_@GIKWQ-^)'P`_X:#^+3ZI
M8>*OVG/&.L_&ZP\%7.K1ZMH/PY\`:KIVB>#OA3X7\$O!-);VWAK4_A?X+\(>
M/;I%AL+K4?&'C3Q7X@U73;#6=:U&TA^XIW,<1<=5:/TY!D4$<@]02,XR,\8.
M#3Q5">`Q=7#^U3K82M[*52C/W8XBDU&I[*I%^]&G64HPJQ=JBBJD;*22F$HU
MZ,9R@N2K#FY)I2O":NE.+5KN+7-%J\7>+U1^8NL_\$6O^"5^O:K?ZQ>_L0?`
M^&\U*YEN[F+2-%U+0-,269MS)8Z)H.K:;HNEVRGB*RTRPM+.!<)#!&@"U4M/
M^")W_!*JRNK>[@_8D^#9FMIHYXA/:>(;N`O$X=5GM;KQ!-:W4+%=LMM<PS6\
M\9:*>*2)V0^&?"O_`(*A?M4_$K]AZS_X*(Q_L6?!M?V=;7P;XM^)_BGPYH/[
M9/B74?CMI7PR^''B;7=%^).NZ1X,\1_LC>#_`(<:_P"(/#6B^%?$GBO2_"L_
MQCT%?$]EI\&E6FN6>MW]MI[_`+%?#CQ]X;^*OP]\"_$_P=<SWGA+XB^#_#7C
MKPO=W5G=Z==77AWQ;HUGKVBW%SI]_#;WUA<3:=?V\D]C>V\%Y:2LUO=0Q3QO
M&OT..QW&.67^MYUFU/V>*K8&;HY[5Q"I8O#)>VP]1X;&U/958)_#4Y>=*7)S
M*,FO%PF&X=QR3PV6X"7-1I8B/M,IA0<Z%=7I58>WPM-SA-1^*',EHI6;2=;X
M:?"OX9_!CPAIOP^^$/P]\$_"WP%HSWTFC^"?AWX6T3P9X2TJ74]0NM6U273O
M#OAVRT_2+*;4]5OKW5-1EMK2*2^U*\NKZ[::ZN)I7Y/XW_LY?`3]I;PU:^#_
M`-H'X-_#3XS>&M/N+J]TO2?B3X,T'Q?!HFI7EC/ID^K^'WUJRNY_#^M&PN;B
MUCUK19;'58(I6%O>1'FJFO?&.71/VDOA3\`/[`%S'\3?@S\?OBY_PE/]J>2=
M%_X4=XR_9L\(?\(^=$_LV;^TO^$G/[0O]HC51J^G_P!B#PC]C.F:O_;_`-JT
M7#^+_P`?G^%?QI_9-^$@\*_VXG[3OQ(^)'P]?7?[<&F?\(6?`/P%^)WQN36/
M[,_L;43XC_M/_A6Y\,_V>-1T#[%_;0UDWUY_9O\`9-_XE*&9>WHXJC4Q$<5B
M*.)S"CBH8IPQ,J=!8EXG$*NJL:L)Q6&Q-[SC5GR-04N>'-Z-2I@'1JX>K&C+
M#TJN&P-6A*AS454Q/U98>@Z7LW"4)_6<.M(NE%3]]Q49\OQY_P`.1/\`@E+_
M`-&2?"#_`+X\4?\`S25M^'O^",?_``2S\,:M::UIO[#WP'N+RR<R01:_X:N/
M%6E,Q1XR+O0O%&H:QH=_'M=OW5]IUQ&&VN%#JK#].*^&OVX?VQ]3_94\,>`=
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M_M'?$3X/>$O%GQP^$<&GVOPX^)&IQ7YU_P`)P:3JFI:WID>FF"^ALB+'5M8U
M.^@^U6EP5GO)2#MVJ.U_9_\`CG\//VF?@I\,OC[\*-7CUOX>_%CP?H_C/PS>
M">QENX+35;</<:/K,6GWE_;Z=XE\/7ZW>@>*=$:[EN]`\1Z9JFB:@(K_`$^Y
MAC]:N&9(7*-M;Y55L`[2S*H;#`@XSG!'.,<=:\=5,7@L164:F(PN)C]8PN(Y
M:E2E67-ST<50JM.,VI^_3K4YMJ7O1FF>@XX;$4:<G&C7H-4ZU)\L*E)J/+4H
MU::LX>[:,Z4XJ\6HR@T[,FHK\9/#'_!1O]K?6/V,M&_;\O\`]C+X(S?L^/\`
M"JV^._B;0?"7[9?BO5?CCH_PBLX!K/C76-*\&>+?V0/`?P[U_P`6>#_"%MK/
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MGA_PYH>E`Q6$<GV;3H,N9#)(_M/COP-X3^)W@GQA\./'FAV?B;P/X_\`"^O^
M"_&/AO41*=/\0>%O%&E76B>(-$OA#)#,;/5-*O;JRN1%+'(89W$<B/AQ\"_M
MO_\`!0NT_8C^+'[-_A?Q3\+;OQ;\*_BY#X^USXP?%>U\;:3X=C_9Y\`^"_'/
MP#^&0^(^K^%M3T:XD\;^%8/&/[0WA&7QFVF>(=$U/P;X2T_6_%D=AXBM-/N[
M2U]\_;'_`&H-,_9,^#$_Q%'A>3XB^//$OB[P9\*/@I\(K'Q/X=\(Z]\9/C=\
M3O$%GX5^&_PUT+6?$\\.G6+ZQK-]_:/B35Q!J<_A3P)H_BWQJVC:M:>&;JRE
MZ)8+.<1_8U>?UBM_:$?J^3U98I3]W`UWA50ISE5MA%A*J5J=1T51I2IUTHT:
MD)O!8G*Z:S*C'V,%A&JN8TE0E%)XFC&LJDX>S2Q#Q%/>=-5?;5(SI-RK0J07
MRK_PY$_X)2_]&2?"#_OCQ1_\TE2P_P#!$K_@E1;RQSQ_L2?!TO$ZR();?Q)-
M&61@P$D,WB%X94)&&CE1XW7*NC*2#]F_LH_')OVFOV9_@-^T._AD>"V^-GPH
M\#?$\^$1K/\`PD0\-?\`":^'K#7QH?\`;W]DZ%_;/]F"^%G_`&G_`&+I7VWR
MOM']GVGF>0GNFI:C8:/I][JNJWMKIVF:;:7%_J&H7T\=K9V-C:0O<7=Y=W,I
M6*WMK:".2:>>5ECAA1Y)&5%8CIKY[Q3A<15PU;/,[AB*%6="K".;8V;C5IR<
M)P4J>)E&34DXWA*2E]EM,BEE>1UJ5.M3RO+)4JM.G5IR_L_#1YJ=2,9PE:5%
M2C>+B[22DMFD[H\X^$7P,^"WP`\-WG@[X%?"/X9_!CPCJ&L7'B*_\+?"GP)X
M7^'OAV^\0W=G8:==Z]>:+X3TO2=-N=9NM/TK2["YU2>V>^GL=,TZTEN'M[&U
MCAY3]HW]EG]GW]KGP3I7PX_:1^%OAOXN>!]$\4V?C72O#GBA;]K"Q\5:?I.M
M:%9:W!_9][8SK>V^D>(]<T^-FF:/[/J=TK1L7!7Y3_8E_P""BFE?M<^.?&/@
M;5_A7XC^#]SJ'A*/X[?LV7WBO51,_P"TG^R7J_CKQ/\`#_PI\??#_AZ_\/>%
MO%/@IM3U/PYIVM:UX&\2Z-/=:#X3^)'PC\00>(=;MO'4*V'Z5UPXN&:Y5F4I
M8FIB<+FE*<:SKQQ+>)C4G%352.*HU9-U/>M.4:KG"HITZCC4A.*Z,-+`8[!J
M.'A1K8&<725%T%&BX1=O9_5ZD(I4[6<(NFH2@XRA>$HM_E9_PY$_X)2_]&2_
M"#_OWXH_^:2C_AR)_P`$I?\`HR7X0?\`?'BC_P":2O<OC7^UOXL\.?'/1?V6
M/V=?@O/\>?C_`'7@:U^*WC5=>\9R_"?X'_!;X9:AK=]X?\.Z[\7_`(O+X,^(
M6HZ?X@^(6L:+XDTWX<_#WX?_``\^(OCC74\,^(/$&LZ1X6\'::WB=]GX:_$O
M]M1/B9X6\'_'/]EOX3:5\/\`Q3I7BR>[^+WP&_::NOB?8_#[7=!M]-O=!TKX
M@^`_BI\$OV?/%#:/XTBN-5TO1/$/PTD^)E_8Z]IUG%XI\*^'/#^I2^)--]?^
MT>+(T%B*F?YE1C*B\1"G7X@G0Q%2@DY1J0P]7&PK-58IRH1Y.?$QM+#QJJ4'
M+@^J9`ZKI1RG!SE&I[*<Z>31G2A5O%.$JT,(Z2Y'959<SA1<6JTJ;1[S\&O@
MQ\+_`-GOX;>&?@_\&/!FD?#WX9^#8M1@\+^#M"6X72=%BU?6=2\0ZDEHMW<7
M5P%O-:U?4=0E\R>0^?=RE2J%47RGX5_L3_LK_!+XR?$?]H3X4_!7PAX)^,_Q
M=F\2W'Q*^(6CKJ8USQ?-XP\30^,O$TFJ&YU&XL]VL^*+>#6KS[-:09O(U,?E
MQDQGZEK\JO@Y^VO^UO\`M(^+/VG=,^!7[+G[.UYX2_9H_:E^*7[+&I>(?BW^
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M>_%SPKX*\%?$&5M3&O\`AKX>>/M;^)_@_31%K&H0Z.='\<>(_AO\(]9UO[;H
M,>EZC?\`VWX>^'CINIWE[I$`U6UL(-;U+R+]H?\`:#D^!7B3]F'0$\*?\),O
M[1G[1^E?L_O=?VX-%;P>-4^$WQ>^*(\6K"=%U@:^;?\`X52=".A&31O-&O\`
M]I_VS$=+%AJ.6#EF-&O6H8#$5J5:I1KTZ_U3%^SA7H4J<JV(A*K2JQIUZ')2
ME/E<I0JJ*Y%)RBGIBOJ;HTZ^,I4YTZ52C4INOA_:2I59RC"C.$)TY5*57FJ1
MBI*,9PYG=Q7-;T#XV_`[X3_M'_#/Q'\&_C?X(T?XC?##Q?\`V.?$O@S7OM9T
MG6#X?U_2O%.BFZ%C=6=R3IWB#0])U6W\NX3%S90[MT>]&^`_^'(G_!*7_HR3
MX0?]\>*/_FCKZV_:E_:'E_9P\-_"7Q%%X4'B[_A9W[2?[/'[/;V9UP:"-&7X
M]_%7PU\,_P#A+OM!T76SJ!\*#7SK0T$0V`US[+_9QUC2//%_!].UMAL?G>6X
M2G/!YAF&!P>)K5^2.$Q]>A3JUZ,:$:\G2H5HVG&,Z,7.<%SKE49247RQ6PN6
M8W$2CB,'@\5B*%.GS/$82E6G"G4E.5-*I5I2O%RC-J,9/E=VTN;7\K/^'(G_
M``2E_P"C)?A!_P!\>*/_`)I*^O-._8[_`&:='_9RD_9&TCX2^'M*_9OET_5=
M)E^$NFW.M6/AN32]>\5WGC?7--D>UU6+59-/UKQ-J%_J.KV3ZB;;4UOKVPOH
MI],N[BSD^<OVI?VH_P!LG]FO0M;\?Q?LR_LT^-_AA#\3_A;\-_#.J3_MA?$_
MPQX]U9_C/\8O!/P7\#:MKO@N+]B3Q#X>\/B#Q#X_T34?%-EI_P`0/$W]D:+:
MZK+I=YXBOX+2QO\`ZQ^#&N_M):VWB9OV@_A=\%/AJEO_`&-_PAZ_![X]>./C
M>-9,HU/_`(2`^(/^$S_9N_9\;PP-/\K1?[)%@?&#:TU]JINSH":59C6>O%XC
MB*K@\-CL9F]?$X:->-7"^USZ.*K4\515&:G2PKQ=2O3Q&'6(I.4U3A4HJ;NT
MN8Y<-3R:.)K87"X"A1K^QY:ZAE4J$98>JYQ4:E;ZK"E.C5=":493<*W(^536
M^E\"O@!\&OV9OAWIGPF^`WP\\._##X=:/>:KJ&G>%?#-M-!80WVMZC<ZMJM[
M+)=3W5[=W=Y?74LDEQ>74\JQ""UC9+2UMH(O8:^8OVT/VBV_9'_97^.7[2J>
M$/\`A/F^#/@34?&__"&?V^/"W_"1C39K9#I?_"1'0_$HT?[0)B/MO]@ZKY6.
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M,=&U&PU9D\?ZOX.^,O[-_P"S]HOC#PAHFJ6VD6WBN'PIX_\`^$]MM/U674O"
M?P_\9W6GMHESW1H9I4P6%;Q*IX*+JXO`T<3F5##1;4I0JXG!X:OB:;M.=.=-
M5Z5-*O6I3I4I5*U*4(\TJV!CB*]J7-7:IX?%5:.$JU7KR.G1Q%>C1G%\L9PF
MX5)OV5&<:DU"E44G[3^SE^RS^S[^R-X(U3X<?LW?"SPU\(_`^M>*;WQKJOAS
MPLE\MC?>*M1TG1-"O=;G.H7M_<->7&D>&]#L'(F$8@TVW58U(8M[_0*^*/VU
M_P!KC5OV7O"WP_TCX8_"B7]HK]I#XV^,W\$?`C]G72OB!X<^'.N?$:^T+1K[
MQK\0]:E\4>([+5[/PYX3^'GP[T/7?$GB'Q+=:+?:7;:D?#'AJ^N-+NO%VF7\
M?)3AC<UQJBISQ>-Q4Y2E5Q-=<TVHN=2MB,5B9J$*=.G&52M7KU(TZ5*$JE6<
M81E);SEA<OPSERPP^&H12C"C2?+!.2C"G2H48.4I2G)0ITJ4)3G.484X.32?
M=_%;]C+]EKXX_%CX8?';XK_`WP!XU^,GP9O]&U+X9_$O4]):+QEX6N?#?B&'
MQ;X;2WUNPGL[R_LO#OB>%]>T'3=7DU#3M&U2]U:\TRUM9M:U=[[Z<KQ?]G7X
M]?#S]J'X'?"_]H'X4ZE_:?@+XK^$-*\7:$TESI=QJ6E->QF+5O"WB)-&U'5M
M.T[QAX-UR#4_"7C70X=2O)/#WBW1-9T*ZF:[TZ<+[),Q6-W!(*`/QC)"D,5^
M96`W@%2=I(!R.0*C$SQ:<<'BYXB^!E4PL,/7G4?U5JK+VM&%.;:I?OG-SC%1
M3FW)ZMLJC'#\KKX>%)1Q*A6E5I0BO;IP7)4E**7M'[/E492NU!1BO=22^`/C
M/_P2M_X)\?M#_$OQ+\8OC7^RS\-_B)\3O&+:2WB;QEKRZ^=6UEM"T+2_#&D&
M[-GKEK;$V.@:+I6EP^5!'_HUC"'WR;G;SS3O^"*?_!*W2[ZUU&U_8B^"KW%G
M/'<0I?:;K>J6;/&=P6ZTW4]<N].OH&^[+:WUK<6LZ$QS0NC,I^KOV-OVAV_:
MS_9:^!G[2;>$?^$";XS_``_T?QT?!O\`;X\4_P#".?VL)6_LO_A(1HGAL:Q]
MG$>/MO\`86E^;G/V2/'/TQ7JU<WXDRVK4RZ><9OAIX"<L'+#4\TQ7L\/+"OV
M+HP5'$.CR4G3Y(^S;IVBN1N-F<-/+LFQE.GBXY=E]:.*A#$QK3P-#GJQKQC5
MC4DZE%5.:I%QE+VEIW;YU>Z/$/@[^S-^SG^SQ_;8^`7P$^#/P0'B?^S_`/A)
MA\(?AAX)^&J^)#I(NUTEO$*^#=$T8:V^EKJ&H#37U3[6U@+^^^R&'[9<^;[?
M7YTZI^U1^TE\1?C[\>?@M^S%\"/@CXKTS]FC6OAQX4^)7C+XY_M,:O\`"F]U
MKQG\0OAQH?Q7CT?P/X$^'7P&^//B,>&-)\'^+O",<WQ!\;-X2L]8\37?B30?
M"GAWQ%#X1U;5U^W?AEK?CCQ)\//!6O\`Q,\#V?PS^(6M>%]$U3QI\/-/\66O
MCNS\$^)+^P@N=7\+0>-+'3-&L?%*Z'>R3:<VNV.EV5EJ3V[75I"+>2,GBQV&
MQM/EQ..JQJ5L1"A6E[3&4*^+<,30C7P\ZM-5ZF)2GAY0G>I!<BE"$^64HQ?1
MA,1A)\U#"0E&E0=2FG##U*6&O1JNC5C2J>SC2DX5E*,E%MR:E./-%2D=S111
M7G':%%%%`!7RY\;OV+/V7OVB+J75?BM\'/"FN^)9I8)YO&>GQ7OA;QM=2VFG
M?V38_P!I>+O"EYHGB#6[;3[`1P6.F:YJ&I:3;BWM<6#+;1*OU'10!^(?C#_@
MA]\'9TMV^&?QH^(_A*X$TTEY_P`)MH_AOX@V;Q/('A@T^WT6+X;75F(!NB\R
M\U#57ECV%L2J\DORE^T+)<?\$%/!_AO]K-47]JI?BIXQM/V:)?`1<?`UM!;Q
M=HFN_%)/&?\`PD^SXQC5!8?\*<?13X=7P_I_VLZ^-1_MZU&E_8=1_IIK^9O_
M`(.I/^3"?@)_V>U\/?\`U1'[1]?2\'9?A,UXGR7+L?2]O@\9C84<11]I5I>T
MIRC)N/M*,Z=6.J6L)QEYGC<0XO$8')<PQ>%J>RQ%"BITJG)"?++VD(WY*D9P
MEHVK2BUY7.?\"_\`!Q'X@^)MI''H?[*FF^%K^\5?)N]3^,LWB>U@D)4[FLK;
MX6^%Y9X\%E,?VVW?JPF'RY^[/@)^W3\?_B^;NS\3CX;:+%J96'2[WP5X0UK3
MM7T:.4*%E:?Q3XS\::1J5Y&=S+)-H4%H2WSV#!<'^,?]F#_F%?\`;.OZ<?V,
MYP]Y;0VEMJ6K7UE:6FJW&D:!I.J>(]?72Y=0MM+&J1^'M!M-1URXTR._NH(+
MK4+?3Y;2SWF6[FAACDD7]/XPX5X?R>A6>7971H2BFXN4J^)DFF]8_6:E9W=N
MG338Y,FQN*Q=*$\16=24HW;Y803=H6TIQBEJ^B2UU/JO]IKQS\3K"RM].N?B
MM\0]1DT6TUFR>_BUY/";:]#JT#6UV/%&B_#RS\&^$M?"VL@M[2*_\.20603[
M3:Q17TMQ=R_FA^RE^PQ/^U[\:X+'6]`N+7]GCX;7]F/BAJ%G-=^'-.OQ#807
MNB_"GPS?:4;.\.MZY9R:?+K4?AR[TZY\$>"+E=8N=5T'5M<^'UOXC_=?4/V2
M]5^,?B(ZG\1WE\(>#;?5(K@:#87UG>^*?%$>E>(]4CN+'5+JR>\TKPYX9\1:
M;I.BW<-SI&IWWBZ\\/\`B;4+,GX;>+=(M[Y/NGPEX0\+^`O#VG>$_!F@Z7X:
M\-Z2MP-/T;1[2*RL;=KV[N-1OIQ#"JA[K4-1N[O4=1O)3)=:AJ-W=7][-/=W
M,\TGP6'XI>497/"Y;RK'8BFX3Q$%RPPJDG%RI\J2E646W3</<IRES-N4>5^M
M/"*M4O57[M--Q>\I1Y;*W\FCYKV;M9*SN;EM;6]G;PVEI!%;6UO&D-O;P(L<
M,$,8"QQ0QH`D<4:@)'&BJB(`JJ%``9>G%M(3G@Q]`6/^M3H%!)/L`35JBOB/
MQUOK?UULT_Q.[RZ'\_G_``2Q_P""4WP3L?V#/V:M*_;$_9RU+6_B_H-EXTO/
M&GPO^-7C'X@>-_`>F:P_Q*\=-H<UY\$/$7C;7?@O#<?\(Y=:9>VAMO!.U9+D
M:GQJ<\URW]`=%%>CF>:8S-L77Q6+K5)NMB<3B8495:M2CAGBJKJSI8>%6<_9
M4D^6$8I_!"";?*CCP.`PV7X>EA\/3C%4Z-&BZBA"-2JJ%-4X2JRA&//.UVW:
MR<I-)79^<O[3?[*_A+]I;]K_`/9GNOBI\.]3\:?"3P+^SQ^U_::IJ-OK?B;P
MYINB_$/QC\0_V)KCP'87>J^%-<T'4GO-<\->#?B;<6-D]S/82PZ'J$US$MS;
MV#'QOQ9^P#\+_@[^V%_P3Z^*/[._P>UC2+'P=\8OC?=?%GQ);^+O'?B>Q\/>
M$-;_`&1/CUX3T*\U:#Q?XLURULH+[QSXA\-Z);7=E:I=M?ZI;6[2"WFEK]?J
M*WHY[F%"C0P].M4CAJ&7X[+OJ\:U:-"I2QZQJJU*E)5.252/UZ?*[*+]G3YH
MNSOSU<GP56K6K2IQ]M6QN#QKK>SI^VA+`O!NE2C4<'/V;6"A&:;ORU*JBUS:
M%?BUX0^!/[=/QU_:P^+O[:-C\1/A_P#LW0>'XO$G[+W[-?P]^.GP`\=_&N^B
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MO`T?BWQ%\7;#28K>[O\`3=$M?U@O&"P.3P!M;H3]V1">`"3P#T!^AJU148_'
M5<QQ#Q>(C26(G3I0KSI05*->I2@J;Q$J<;0C5JPC!UO9QC"=12J\JE4E=X7"
M0PF'^K4Y3=*,JCIJ<I3=.G4DY^RC*;E-P@Y25/FD^2')37NP1_+7X*_X):>)
M/!7[!_[$WQ>MO@KK/Q.^.'[/G@O0O$/Q_P#V'/CSKFO?%/X4?M!Z'?Z3'H_C
MSP-;?#3XD>)_$7@/X=_&KP78/<>*O@3XD\*:-;:#IOC:TD\+>)?"^O:+XH6X
M\/?T]^'M93Q#H.BZ]%8:KI4>M:58:M'IFNZ=<Z1K>GIJ%K%=)8ZQI-XD=WIF
MJ6BRB#4-/N8TGLKM);:91)&P&S179FV=XS.7&6-:G*GBL=7I3YJK=.ECJOMY
M85*=24'2HU>9T:CC[?DG[&I5J4:6&IT,,ORS#Y;%QP]U&5##4IKEIQYYX:DJ
M2KODA%^TJ17[R*:I<RYX4XU)UIU?SY_:$^!TOQC_`&Q?V?\`_A*?`LGB_P""
M%S^R3^W;\(/BV]Y;M+X;D@^,_B']D&VTSP;KC)-!*1XV\-^#?'L,4=NVXVFC
M:EF>WD$#2?(?[&G[+?[4T?QU\)V?[6-W<ZS\(/\`@F_X7\3_``<_8_\`$L_B
M'4K_`%3]H;6?'\.IZ;HW[2?CS3M,E\.6'_"7_"S]EJ^\'?L_Q6^N>&/%0O?B
M-XJ^/_BW3?%4E[=V_P!G_<*BG2SW&4<$\#3C0]FL)+"4JLH3E7P_M,1C:M:M
MAY^T4:=2O0S#%8&NE!TZN%FE.#K4J-6G$\IP\\5]:E4K.3Q*Q$H)P5.;C0PM
M*E3J1Y'SPH5,'0Q-&[3C6C*[E3J583^+_P#@G-X$\7_"[]@O]CSX;_$#0-0\
M*>.?`G[./PA\)^+_``UJJ)%J6@^(]"\$Z/INL:1?)&\L:W>GWUO/:SA)'021
MML=EP3XM_P`%,_`/[0G[27P^\'?L6_`FVU3P?HG[36J>(?#W[0/[05SH<^N>
M"_A%\!?#&@_V[XN\/ZE8Z3\0_A]XFU7Q/\;]1DT/X4:5X?T6]>'4O!>N?$:3
M4]8\)O;:7K:?IS16,<TK+-:F<.G0EB98C$8R$)0<J-+%593J4:RIRDU/ZK6E
M&M3IU>>E4G3C&O"I2<Z<M98"$\OAEKJU51CAZ.%E.#Y*M2A2C3IS@Y1LX^WI
M0E3J2I\DXQJ2=.4)J,U^%'[3/[(7_!0#PS9?`W]I#X<_%G]FSXI_$C]AO5+C
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M&\^-_P`-?'/[/>E^.=&\#_$?P!X2\6>)/">C^//AMJ_@OQ4="\;>!?#5_J'Q
M2M_$^FZ5XB\&:)XIMM1UG0K?Z"^'_P"V#X@^,/Q&\'^%/A=^RS^TH?`5Y=W/
M_"R_C)\:OAQKG[,_ACX>:<OA'Q9JVGP:5X)^.&G>$?C!\3/$VH^+-)\,>%OL
M7@[X=R^#=.L/$U[XCU+X@6KZ#!H6O?;%%55S"GB*=-XG!TJV*I82E@J>)]KB
M(<U'#T(X;#2K4HU+3K86A3I4\/*G*C2<:-/ZS1Q+YW-4\%.C.?L<55IT*F(J
M8F=#DHSM4K5'6K1IU)PE*-.O6E4J5E+VD^:K/V-2@N51*_E_^#?[-?@+P7\7
MOV]M4_:C_8%_:S^+.N?%#]OK]H#XJ_"WQO\`"[3?$<GA;5_@WXIC\(V_A6YB
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M&4+Q?XO_`!V^)WQ"_;R\0_LJ_"OX(?LZ_M#^"_#_`(#_`&LOV=/VB?CG\4/V
MBO@YXL^`7A+X?^"?@%XR3XJWW@_0K7XGQ^&/%7Q,^(WBOQ-X5\.^#M#_`.%6
M^&O'?@&SCUNYUOQ#XUT?2K:"\G_:"BBGB\9'$4\/AZ-".&PV%]LZ=-3E5G*I
M7E&56I5JSMS2?)"$5"%.G&E3@N1U/:5:AA\,Z-2M6J576KU_9J<^2-.,84HM
M4Z<(1O9)RG-RE*<Y3G+WE!0A#X>_X*'>`O&/Q+_9LC\)^`O#NI>*?$?_``T)
M^QGXI_L?28EFO3X>^'_[97P"\?>,]5$;.@:V\/>#_#6NZ_?[29!8:9<M$DDB
MK&_W#1164\3.>$H8-QC[/#XC%8F,E?G<\73PE.<9:\O+%8.FX62=YSNVN51T
MC0A'$U<2G+GK4:%"2=N51P\\1.+6E[R>(DI7;^&-K:GP!_P50^&WCKXP_P#!
M/#]KCX7_``R\,:GXS\?^-_@]KV@^%/"VC)'+JNN:O=3V1M]/L(I9(8Y+B78V
MQ6E0'!YK[_%%%$L3.6#H8)QC[.ABL7BHS5^=SQE'`T9QEKR\L8X&FX6BG><^
M9M<JB1H1CB:N)YI.56A0H..G+&.'GB:D9+2_-)XF2E=M6A#E2?,Y?F+^TU\%
M/BS\.?VQOA/_`,%"/@5\.;KXY:OX>^!GB_\`99^._P`%=.\2>&_#OCG7O@UX
MF^('A;XE>&_&?P1N?&VO^#O`,GQ#\#>-]&N[GQ#X=\;^+=(T_P`;>"M2NM,T
M+4=,\4Z9I*ZIZ%HO[<6N?$/7?"'A7X/?L@?M:>(]:U?Q#X5LO'>H?%?X2:]^
MS1X'^$OA>_\`%>C:3XR\1^(?&7QPM?"MMX_OO"OABZUWQ'I/AKX$V'Q;N?%U
M_H]EHT5]HVEZP_BK2_OBBNK^T*=2AAZ6*P=+$U,'1EA\/6=7$4FZ+G4J0IXB
M-.HO;*C.K-T94W0J)-0JSJTX4X1YU@I4ZU:IA\3.C#$U8UJ]/V=*I^\4(4W*
MC.<6Z;J1IQ]JIJM%N\J<:<Y2DROQ<\/_``,_;E^/7[8'Q;_;$T[QWX#_`&:=
M/^'\7B7]EK]F7P'\=/@%XU^-;W_P6T[4O#FN>/\`X^Z7H/A7]KGX0:%X/\0_
MM`?$K1S:/-K_`((M?'$GPJ^%OPJLYQIMI/?#6?VCHK/`YA5P"Q3H4Z$JF*H/
M#.I7H4L0J="<DZ\84J\*E%NO&*I3E.G)JE*I"-O:-FF*P=/&>Q56=94Z-55E
M3I59T>>K&+5.4ZE)PJVI.3J1C&<8NHH3DI.G&WY)_L9_";]J?]DS]J#XS_"/
MXF:CI7QA_9^_:0;Q1^U!X2^+'P\\#^*?A]X'^$?[1.N>)Y?^%W_!X_#_`,6?
M&'X]^(?#'AWXJ?VCIWQT\/:HOC+0_`T7Q`O_`(KZ3H6A6EWK]EI]O^LMR<6\
MQ_Z9M[]O8?TJ>BIQ^.JYCB%BJ\*,:[I4(5I4::I0KU*$536(G2@U3A5J0C35
M7V4:<)SBZO(IU)N3PF$A@Z+P].=25%5*DJ4:DG-TH5'SNC&<FYRIPFYNGSRE
M*$)*FI.$(I?A[_P3W^/OQ$_9E_8F_9E^`'Q(_8H_;6/CWX4_"WPWX+\4MH/P
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M[U154X0I4J,9^VG";GB/91C]8K4N14\/5DHRIT)3A+VDYSJ,HHHKR3T`HHHH
M`****`"OPO\`^"\?[,7C?]LGX.?L6?LV?#Z:TLO$7Q-_;Z\"6<NK7S6QM/#O
MAG0OV<OVH/%'C7Q1-;W-_IBZB/#/@_1-;UR+1X;^VO-<N+&'1=/E_M#4+1'_
M`'0JI<6%E=S6-S<VEM<7&FW$EWIT\\$<LMC=2VES82W-G(ZEK:XDL;R\LGFA
M*2-:7=S;EC#/*C>GDV:5LES/"9IAU%XC!SG5H<ZO!5G2G"G.4;/FC"<E.4/M
MJ+C=7NN+,<#3S+!UL%6<E1Q'LXU7%VE[-583FHOHY1BXJ5FXWNDVK'Y;?LK?
M\$<?V)?V8/#VBVQ^'J_&CQK9Z5<Z?K/CCXPRR>*H-:DOYH+F\DC^'<TH^&>E
MPVTD"6FARP>%9_$&G:2OV.]\1ZO=76J:CJ/Z:^%_"OAGP3H6F^%_!WAW0_"G
MAK1K6.QT?P]X;TFQT/0])LH1B*STS2=-@MK"PM(LL8[>U@BA0LQ5`6)._166
M.S/,<SJRK9ACL5C*LI.3E7K3J)-[\L')P@NT8145HDE9&]##T,-"-.A2A2A!
M*,8Q6R226NK>BW;;>[U"BBBN$V"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
0*`"BBB@`HHHH`****`/_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
